

mecA Gene Is Widely Disseminated in *Staphylococcus aureus* Population

C. L. C. Wielders,* A. C. Fluit, S. Brisse, J. Verhoef, and F. J. Schmitz

Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation,
University Medical Centre, 3584 CX Utrecht, The Netherlands

Received 11 March 2002/Returned for modification 28 May 2002/Accepted 4 August 2002

Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the most important causes of hospital infections worldwide. High-level resistance to methicillin is caused by the *mecA* gene, which encodes an alternative penicillin-binding protein, PBP 2a. To determine the clonal relationships between methicillin-susceptible *S. aureus* (MSSA) and MRSA, we typed 1,069 *S. aureus* isolates (493 MSSA isolates and 576 MRSA isolates), collected mainly in North American and European hospitals between the 1960s and the year 2000, using pulsed-field gel electrophoresis and ribotyping. Of 10 widespread *S. aureus* lineages recognized, 8 had corresponding *mecA*-positive strains. Multiresistant MRSA strains are found in hospitals worldwide, while unrelated and more susceptible strains represent less than 1% of the MRSA population. This supports the hypothesis that horizontal transfer plays an important role in the dissemination of the *mecA* gene in the *S. aureus* population.

Staphylococcus aureus strains resistant to methicillin and many other antibiotics are major causes of nosocomial infections worldwide (8). Resistance to methicillin is determined by the *mecA* gene, which encodes the low-affinity penicillin-binding protein PBP 2A (3). The *mecA* gene is part of a 21- to 60-kb staphylococcal chromosome cassette *mec* (SCC*mec*), a mobile genetic element that may also contain genetic structures such as Tn554, pUB110, and pT181 which encode resistance to non- β -lactam antibiotics (15). Two hypotheses have been raised to explain the evolutionary origin of methicillin-resistant *S. aureus* (MRSA) strains. The single clone hypothesis, based on early analyses of the restriction fragment length polymorphisms obtained for MRSA isolates collected worldwide by using probes for *mecA* and Tn554, suggests that *mecA* entered the *S. aureus* population on one occasion and resulted in the formation of a single MRSA clone that has since spread around the world (15, 16). The second hypothesis, based on the detection of *mecA* in diverse *S. aureus* multilocus enzyme electrophoresis types, proposes that MRSA strains evolved a number of times by means of the horizontal transfer of *mecA* into phylogenetically distinct methicillin-susceptible *S. aureus* (MSSA) precursor strains (17). By using DNA microarray technology, *mecA* has been detected in at least five divergent lineages, implying that horizontal *mecA* transfer has played a fundamental role in the evolution of MRSA (9). The transfer of *mecA* from *S. epidermidis* to *S. aureus* was recently witnessed in vivo, suggesting that *mecA* may transfer more frequently to MSSA (21).

MRSA is also emerging in the community, particularly in the United States, where 28% of community-acquired *S. aureus* strains may be resistant to methicillin (4, 5, 8, 11). The prevalence of MRSA in the community is predicted to increase

substantially due to the dissemination of a successful SCC*mec* type by horizontal transfer (5, 13). We present molecular typing data that support the theory of frequent *mecA* gene transfer into resident lineages of *S. aureus*, with the resulting formation of numerous MRSA clones. The population framework that we established can be exchanged between laboratories by use of automated ribotyping.

MATERIALS AND METHODS

Bacterial isolates. The clonal relationships and antimicrobial susceptibilities of 1,069 *S. aureus* isolates, including 576 *mecA*-positive (*mecA*⁺) isolates (which are, by definition, MRSA) and 493 *mecA*-negative (*mecA*[−]) isolates (which are MSSA) were determined. These isolates were selected from different sources in order to study isolates from different temporal and geographic backgrounds. The origins of the isolates were as follows (Table 1): 397 MRSA and 260 MSSA isolates had been collected between April 1997 and December 1998 in 20 university hospitals in 12 European countries as part of the SENTRY Antimicrobial Surveillance Program (10). They included isolates from Athens, Greece (8 *mecA*[−] isolates, 19 *mecA*⁺ isolates); Düsseldorf (10 *mecA*[−], 9 *mecA*⁺) and Freiburg (14 *mecA*[−], 2 *mecA*⁺), Germany; Lausanne, Switzerland (56 *mecA*[−], 1 *mecA*⁺); Linz, Austria (7 *mecA*[−], 7 *mecA*⁺); Paris (group 1) (10 *mecA*[−], 21 *mecA*⁺), Paris (group 2) (7 *mecA*[−], 33 *mecA*⁺), Lille (7 *mecA*[−], 22 *mecA*⁺), and Lyon (7 *mecA*[−], 14 *mecA*⁺), France; Coimbra, Portugal (16 *mecA*[−], 70 *mecA*⁺); Warsaw (7 *mecA*[−], 17 *mecA*⁺) and Krakow (5 *mecA*[−], 5 *mecA*⁺), Poland; Madrid (14 *mecA*[−], 2 *mecA*⁺), Seville (18 *mecA*[−], 29 *mecA*⁺), and Barcelona (7 *mecA*[−], 6 *mecA*⁺), Spain; Rome (10 *mecA*[−], 32 *mecA*⁺) and Genoa (9 *mecA*[−], 34 *mecA*⁺), Italy; Brussels, Belgium (10 *mecA*[−], 31 *mecA*⁺); London, United Kingdom (26 *mecA*[−], 36 *mecA*⁺); and Istanbul, Turkey (12 *mecA*[−], 7 *mecA*⁺). An additional 181 MSSA and 54 MRSA isolates had been collected between 1996 and 1999 at the University Medical Center (UMC), Utrecht, The Netherlands, where patients and staff coming from foreign hospitals are screened for MRSA carriage. These MRSA isolates, detected during 12 MRSA outbreak episodes, had evaded the hospital's search-and-destroy procedure and could not be linked epidemiologically to any foreign hospitals. One hundred three more MRSA isolates were selected to represent the genetic diversity of the MRSA collections of Kreiswirth et al. (16), Roberts et al. (18), de Lencastre et al. (7, 19), and Witte et al. (22). They included the earliest isolates collected from Europe and Africa during the 1960s, North American isolates collected from the 1970s to the 1990s, and European reference strains like the Iberian clone (7), the Brazilian clone (7), the North German clone (22), the South German clone (22), the Berlin clone (22), the Hannover clone (22), the Portuguese clone (7), the Pediatric clone (19), EMRSA 15 (14), and EMRSA 16 (14). Another 12 MRSA isolates that had been collected in South Africa during 1998 were studied. For comparison, MSSA strains ATCC 29213 and ATCC 12600 were included. Fi-

* Corresponding author. Mailing address: Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, University Medical Centre, Room G04.614, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Phone: 00 31 30 2506534. Fax: 00 31 30 2541770. E-mail: c.wielders@azu.lab.nl.

TABLE 1. Origins of isolates

Collection	Description (reference)	No. of isolates	
		<i>mecA</i> ⁻ (n = 493)	<i>mecA</i> ⁺ (n = 576)
SENTRY	European antimicrobial surveillance program (1997–1998) (10)	260	397
UMC	Dutch hospital with MRSA prevalence < 1% (1996–1999)	181	54
Chicago	Samples from community in Chicago	50	10
ATCC ^a	Control strains ATCC 29213 and ATCC 12600	2	
South Africa	Samples from different hospitals		12
W. Witte	Selected European MRSA genotypes (22)		20
H. de Lencastre	Selected European MRSA genotypes (7, 19)		4
B. Kreiswirth	Selected European, African, and American genotypes 1960–1990 (16)		45
R. B. Roberts	Selected MRSA genotypes from New York City hospitals (18)		34

^a ATCC, American Type Culture Collection.

nally, 10 MRSA and 50 MSSA isolates that had been taken from colonized patients who had no clinical signs of *S. aureus* infection within 2 h after admission to the Cook County Hospital (Chicago, Ill.) were included.

The isolates were identified as *S. aureus* by routine microbiological methods. Only one isolate per patient was included.

Susceptibility testing. Susceptibility to oxacillin, erythromycin, clindamycin, rifampin, chloramphenicol, ciprofloxacin, gentamicin, and tetracycline was determined by the broth microdilution method defined by the National Committee for Clinical Laboratory Standards. Isolates were considered multiresistant when they displayed a decreased susceptibility to at least four of the eight antimicrobial agents tested.

Detection and amplification of *mecA* by PCR. PCR was used to detect *mecA* DNA in methicillin-resistant isolates. A few colonies were picked from blood agar; suspended in 200 µl of a lysis buffer containing 10 mM Tris-HCl buffer (pH 8.0), 50 mM NaCl, lysostaphin (100 µg/ml), achromopeptidase (100 µg/ml), and RNase (100 µg/ml); incubated at 30°C for 45 min; boiled for 5 min; and then diluted by the addition of 400 µl of TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA). For the PCR, 1 µl of lysate was added as a template to 24 µl of a reaction mixture containing 10 mM Tris-HCl (pH 9.0), 1.5 mM MgCl₂, 50 mM KCl, 0.1% Triton X-100, 0.2 mM each deoxynucleoside triphosphate, and 0.75 U of Supertaq DNA polymerase (HT Biotechnology, Cambridge, United Kingdom). *MecA* DNA was amplified with the primers 5'-GTT GTA GTT GTC GGG TTT GG-3' and 5'-CTT CCA CAT ACC ATC TTC TTT AAC-3' (20 µM). These primers were designed on the basis of the *mecA* sequence (GenBank accession no. X52593) with Primer software (Educational Software, State Line, Pa.). To test the quality of the template used for PCR, we added primers for the amplification of 16S ribosomal DNA (5'-AGG CCC GGG AAC GTA TTC AC-3' and 5'-GAG GAA GGT GGG GAT GAC GT-3') (20 µM) to each PCR mixture and monitored the amplification of 16S ribosomal DNA. Samples were subjected to 30 cycles consisting of 1 min at 95°C, 1 min at an annealing temperature ramped from 65 to 55°C during the first 10 cycles, and 1 min at 72°C in a thermocycler. The PCR product was visualized on a 1.5% agarose gel by using ethidium bromide and a UV transilluminator.

Pulsed-field gel electrophoresis (PFGE) analysis. Genomic DNA was digested with *Sma*I and resolved with the CHEF-DRII system (Bio-Rad Laboratories, Hercules, Calif.), as described by the manufacturer.

Ribotyping. Ribotypes were determined with an automated riboprinter system (Qualicon, Wilmington, Del.) and *Eco*RI, as described by the manufacturer.

Analysis of restriction patterns. The restriction patterns were compared by calculating a similarity index by using the unweighted pair group method with arithmetic averages cluster algorithm and the Dice coefficient provided by the Bionumerics software (Applied Mathematics, Kortrijk, Belgium).

RESULTS

Clonal relationships among *S. aureus* isolates. When the PFGE patterns of 576 MRSA isolates and 493 MSSA isolates were compared in a dendrogram, 10 major clusters of various sizes were discerned. To confirm the clonal relatedness of the isolates within these clusters, 330 isolates were selected for ribotyping, which covered the chromosomal diversity of the isolates (Fig. 1). Compared to the diversity of the PFGE patterns, the riboprints were much more conserved during evolu-

tion. Ten clusters were distinguished at the 80% similarity level, and these 10 clusters defined clonal lineages called *S. aureus* types I to X (Fig. 2). A very good correlation between PFGE typing and ribotyping was observed: except for the type IV isolates, 99% of the isolates typed by both methods clustered in corresponding branches of both the riboprint and the PFGE dendrograms. The PFGE patterns obtained for the type IV isolates were found not only in a cluster of their own but also in the PFGE clusters of other types as well (Fig. 1). Furthermore, both type II and type III isolates could be divided into two subtypes (subtypes a and b) that formed subclusters in the ribotyping dendrogram and that had different susceptibility patterns.

The more successful *S. aureus* types consisted of isolates which displayed numerous band-shift variations on widely disseminated and frequently isolated dominant PFGE patterns (Fig. 1). Pandemic clones of isolates yielding identical PFGE patterns were present in many hospitals on both continents. Of the type I (40% of all samples), type II (20%), and type III (12%) lineages, indistinguishable isolates were present in nearly all hospitals studied. Type IV (8%), type VI (8%), type IX (7%), and type VIII (2%) clones were also detected in Europe and North America, although less frequently. Isolates of the remaining lineages (type V [2%], type VII [0.5%], and type X [0.5%]) were referred only from European countries.

Dissemination of *mecA* in the different *S. aureus* lineages. All isolates was assessed for the presence of *mecA* by PCR. *MecA* was detected in representatives of all but the type IX and X lineages. Some pandemic *mecA*⁻ MSSA clones came with *mecA*⁺ MRSA counterparts that shared the identical ribotype, while their PFGE patterns differed by a single band shift due to insertion of a fragment containing *mecA* (Fig. 3). However, we found no *mecA*⁻ counterparts among type IIb and type IIIb isolates, which, with no exception, all contained *mecA*.

More than 60% of the *mecA*⁺ isolates belonged to the type I lineage. These isolates predominated in North America, Africa, and Europe. The type I MRSA isolates included all MRSA isolates from the 1960s, the Brazilian clone (7), the North German clone (22), the Hannover clone (22), the Iberian clone (7), and the Portuguese clone (7). One-quarter of the *mecA*⁺ isolates belonged to the type II lineage. Isolates of the type II lineage were dominant among the North American isolates from the 1980s and were later isolated in Europe and Africa. Type IIa MRSA isolates (14% of the *mecA*⁺ isolates) included the Pediatric clone (19). Type IIb MRSA isolates




FIG. 1. PFGE patterns from European and North American MSSA ($n = 493$) and MRSA ($n = 576$) isolates form 10 clusters. Isolates containing *mecA* are indicated by hyphens. In order to confirm the clonal relatedness of the isolates within the 10 clusters, a total of 330 MSSA and MRSA isolates representing the various PFGE types encountered were selected for ribotyping (indicated by hyphens). The positions of the type IV isolates in the PFGE dendrogram are indicated by black lines.




FIG. 2. Ten clusters were obtained by ribotyping of 330 isolates, which represented the variability of PFGE types encountered. These clonal *S. aureus* lineages were called types I to X. There was an excellent correlation between PFGE and ribotyping. Except for the type IV isolates, 99% of the isolates typed by both methods were found in the corresponding PFGE and ribotype clusters. Isolates containing *mecA* are indicated by hyphens. Automated ribotyping allows standardized exchange of data between laboratories.

(11% of *mecA*⁺ isolates) included the South German clone (22).

Type III MRSA isolates were found among isolates recovered since the 1980s in Africa, Europe, and North America. Type IIIb MRSA isolates (6% of *mecA*⁺ isolates) included EMRSA 16 (14). In contrast, type IIIa, type IV (the Berlin clone [22]), type V (EMRSA 15 [14]), type VI, type VII, and type VIII MRSA strains, which appeared during the 1990s, were isolated only sporadically (<1% of *mecA*⁺ isolates). Interestingly, these sporadic MRSA types were relatively abundant among the different UMC genotypes (33% type IIa, type IV, and type VI isolates), which are epidemiologically unlinked to the hospital epidemic MRSA isolates, and among the *mecA*⁺ isolates from the community in Chicago (20% type IV isolates).

Multiresistance and dissemination of MRSA in Europe. To correlate the resistance profiles of MRSA strains with their current dissemination, the susceptibilities of the recent European *S. aureus* isolates were compared. The *mecA* gene was present in all isolates resistant to four or more antibiotics. Moreover, this multiresistance was displayed by the most prevalent and geographically widespread MRSA types (types I, IIa, IIb, and IIIb), which together represented 99% of the *mecA*⁺ population in Europe. Of the European isolates that appeared to be susceptible to methicillin in the phenotypic test, 10% nevertheless contained *mecA*, and some of these were multiresistant. In contrast, 5% of the phenotypically methicillin-resistant isolates did not carry *mecA* and displayed low-level resistance (>8 µg/ml).

Most of the type I MRSA isolates, representing 68% of the recent European MRSA population and being present in 17 of 20 hospitals participating in the SENTRY program, were




FIG. 3. PFGE patterns of *mecA*⁺ and *mecA*⁻ counterparts (upper panels) that differ by a single band shift (arrowhead) due to the insertion of a fragment that hybridizes with a *mecA* probe (lower panels). The type II and type VI MSSA PFGE patterns are for control strains ATCC 29213 and ATCC 12600, respectively.

resistant to erythromycin (97%), gentamicin (98%), and clindamycin (89%) and showed decreased susceptibility to ciprofloxacin (98%), tetracycline (98%), and rifampin (98%). Although most of the type IIB MRSA isolates, which represented 16% of the recent European isolates and which were found in 5 of 20 hospitals participating in the SENTRY program, were resistant to erythromycin (98%), clindamycin (88%), ciprofloxacin (98%), and gentamicin (100%), they remained susceptible to tetracycline (98%) and rifampin (100%). Type IIIB MRSA isolates, which represented 8% of the recent European MRSA isolate population and which were found in 2 of 21 hospitals participating in the SENTRY program, were resistant to erythromycin (100%), ciprofloxacin (100%), and clindamycin (84%) but remained susceptible to rifampin (100%), tetracycline (100%), and gentamicin (84%). Also, the type IIA MRSA isolates, which represented 7% of the MRSA isolate population and which were found in 6 of 20 hospitals participating in the SENTRY program, were mostly resistant to erythromycin (75%), clindamycin (69%), and ciprofloxacin (90%) but remained susceptible to rifampin (100%), tetracycline (100%), and gentamicin (100%). In contrast, type IIIa, type IV, type V, type VI, type VII, and type VIII MRSA isolates, which were isolated only sporadically (<1% of recent European *mecA*⁺ isolates), mostly remained susceptible to all but the β -lactam antibiotics (clindamycin, 100%; tetracycline, 100%; gentamicin, 100%; rifampin, 100%; erythromycin, 60%; ciprofloxacin, 60%).

DISCUSSION

The *mecA* gene, which lies in the SCC*mec* resistance island (13), is carried by 95% of the isolates that display a phenotype of methicillin resistance and was detected in all multiresistant *S. aureus* isolates. This study aimed to examine the dissemination of *mecA* in the *S. aureus* population. Two methods were applied to determine the clonal relationships between *mecA*⁺ MRSA and *mecA*⁻ MSSA isolates collected between 1960 and 2000 from over 50 locations in the Western world. The overall chromosomal organizations of the isolates were first compared by using *Sma*I-generated PFGE patterns, which provide a relatively quickly evolving genotypic marker. Because there is little evolutionary pressure to conserve the *Sma*I restriction sites per se, this technique has high discriminatory power and highlights some of the differences between the strains. Ribotyping was then used to combine evolutionarily closely related PFGE types into clonal lineages. The complete ribotyping procedure has been automated and is coupled to a database management system, allowing electronic data exchange between different centers. The genes that encode ribosomal DNA are more conserved during evolution and provide a relatively slowly evolving marker. Therefore, automated ribotyping results in fewer ribotypes compared to the diversity of PFGE types. Combination of PFGE and ribotyping allowed grouping of all geographically widespread isolates in distinct clonally related lineages except for some of the type IV isolates, which may be ancestrally related to many types.

S. aureus isolates of 10 different lineages, called types I to X, were present in the hospitals studied, and 8 of these have acquired *mecA*. Our data show the worldwide dissemination of both successful MSSA strains and successful MRSA strains.

From the major lineages, both pandemic MSSA and MRSA clones yielding identical PFGE patterns were collected in many European and North American hospitals and the community. Several pandemic *mecA*⁻ MSSA clones have *mecA*⁺ counterparts that share identical ribotypes, while their PFGE patterns differ by a single band shift due to acquisition of the element containing *mecA*. The worldwide appearance of specific MRSA clones has been shown before (7), but the existence of widespread MSSA counterparts was not described before in detail. In line with this observation, a comparison of MRSA and MSSA isolates isolated in the United Kingdom and Denmark in the early 1960s suggests that contemporary MSSA isolates served as an early recipient of the *mecA* gene in Europe (6).

The dissemination of particular MRSA lineages is correlated with their resistance profiles. The majority of the multiresistant type I MRSA isolates, predominant on both continents, lacked susceptibility to tetracycline, erythromycin, clindamycin, gentamicin, ciprofloxacin, and rifampin. A second multiresistant lineage (type IIB), found in North America and several European countries, was susceptible to tetracycline and rifampin. Smaller pandemics were caused by isolates susceptible to gentamicin, tetracycline, and rifampin (type IIA and type IIIB). Although antibiotic selection pressure by itself provides a reasonable explanation for the widespread dissemination of such multiresistant strains, additional factors, e.g., modifications in expression of virulence factors and binding capacities, may add to their high prevalence. In contrast, the sporadically isolated *mecA*⁺ MRSA types, type IIIa and types IV to VIII (1% of recent European isolates), generally remained susceptible to all except the β -lactam antibiotics. Sporadic MRSA types were overrepresented in the samples from the community in Chicago (20%) and UMC (30%), where the search-and-destroy procedure prevents epidemic MRSA strains from entering the hospital, keeping the prevalence of MRSA isolates below 1%. In both the community and the hospital, sporadic MRSA types, which are not descendants of the epidemic hospital clones, may be formed de novo by the horizontal transfer of *mecA* to resident MSSA lineages, as was witnessed recently in vivo when the gene was passed from *S. epidermidis* to *S. aureus* during antibiotic treatment (21).

Several investigators (2, 9, 17, 21) have questioned the hypothesis that the gene entered *S. aureus* on only one occasion. The data presented here show the repeated horizontal transfer of *mecA* to at least eight resident *S. aureus* lineages and the spread of more resistant clones favored most by antibiotic selection pressure. When DNA microarray technology was used to characterize the genetic diversity of 11 MRSA isolates, *mecA* was detected in at least five highly divergent chromosomal genetic groups (9). In addition, multilocus enzyme electrophoresis data showed that MRSA isolates comprise 15 electrophoretic types that form six clusters or lineages, indicating that multiple MRSA lineages arose by horizontal transfer to *S. aureus* (17). Analysis of the *mecI* and *mecR1* region, which lies 5' of *mecA*, revealed that older isolates lacked part of this region, whereas more recent isolates showed an organization at this position similar to that in coagulase-negative staphylococci (CoNS) (2, 12), and it has been proposed that CoNS serve as donors for the transfer of the *mecA* gene to *S. aureus* (1, 20, 21). In this context, it is noteworthy that 70 to 75% of all

CoNS worldwide are now resistant to methicillin (8), thus representing a huge potential reservoir of resistance. The mechanism of transfer, however, remains unclear. There is evidence that *mecA* resides within a mobile genetic element, *SSCmec*, that encodes recombinases for its excision from and integration into the staphylococcal chromosome (15). This element may also contain other genetic elements, like Tn554, pUB110, and pT181, which encode resistance to non- β -lactam antibiotics, causing multiresistance (15). Thus, while new MRSA strains will continue to emerge by the horizontal transfer of the *mecA* gene, those strains disseminated widely possess additional resistance traits and are favored most by antibiotic selection pressure.

ACKNOWLEDGMENTS

We acknowledge B. Kreiswirth, R. B. Roberts, H. de Lencastre, and W. Witte, who collected many of the isolates. In addition, we thank Adrienne Box, Mirjam Klootwijk, Karlijn Kusters, Stefan de Vaal, and Roland Geisel for proficient technical support and Max Heck for advice on PFGE.

REFERENCES

1. Archer, G. L., and D. M. Niemeyer. 1994. Origin and evolution of DNA associated with resistance to methicillin in staphylococci. *Trends Microbiol.* **2**:343–347.
2. Archer, G. L., D. M. Niemeyer, J. A. Thanassi, and M. J. Pucci. 1994. Dissemination among staphylococci of DNA sequences associated with methicillin resistance. *Antimicrob. Agents Chemother.* **38**:447–454.
3. Beck, W. D., B. Berger-Bachi, and F. H. Kayser. 1986. Additional DNA in methicillin-resistant *Staphylococcus aureus* and molecular cloning of *mec*-specific DNA. *J. Bacteriol.* **165**:373–378.
4. Centers for Disease Control and Prevention. 1999. Four pediatric deaths from community acquired methicillin-resistant *S. aureus*—Minnesota and North Dakota, 1997–1999. *Morb. Mortal. Wkly. Rep.* **48**:707–710.
5. Chambers, H. F. 2001. The changing epidemiology of *Staphylococcus aureus*? *Emerg. Infect. Dis.* **7**:178–182.
6. Crisostomo, M. I., H. Westh, A. Tomasz, M. Chung, D. C. Oliveira, and H. de Lencastre. 2001. The evolution of methicillin resistance in *Staphylococcus aureus*: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. *Proc. Natl. Acad. Sci. USA* **98**:9865–9870.
7. de Sousa, M. A., I. S. Sanches, M. L. Ferro, M. J. Vaz, Z. Saraiva, T. Tendeiro, J. Serra, and H. de Lencastre. 1998. Intercontinental spread of a multidrug-resistant methicillin-resistant *Staphylococcus aureus* clone. *J. Clin. Microbiol.* **36**:2590–2596.
8. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, and M. Beach. 2001. Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. *Clin. Infect. Dis.* **32**(Suppl. 2):S114–S132.
9. Fitzgerald, J. R., D. E. Sturdevant, S. M. Mackie, S. R. Gill, and J. M. Musser. 2001. Evolutionary genomics of *Staphylococcus aureus*: insights into the origin of methicillin-resistant strains and the toxic shock syndrome epidemic. *Proc. Natl. Acad. Sci. USA* **98**:8821–8826.
10. Fluit, A. C., C. L. Wielders, J. Verhoef, and F. J. Schmitz. 2001. Epidemiology and susceptibility of 3,051 *Staphylococcus aureus* isolates from 25 university hospitals participating in the European SENTRY Study. *J. Clin. Microbiol.* **39**:3727–3732.
11. Herold, B. C., L. C. Immergluck, M. C. Maranan, D. S. Lauderdale, R. E. Gaskin, S. Boyle-Vavra, C. D. Leitch, and R. S. Daum. 1998. Community-acquired methicillin-resistant *Staphylococcus aureus* in children with no identified predisposing risk. *JAMA* **279**:593–598.
12. Hiramatsu, K. 1995. Molecular evolution of MRSA. *Microbiol. Immunol.* **39**:531–543.
13. Hiramatsu, K., L. Cui, M. Kuroda, and T. Ito. 2001. The emergence and evolution of methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol.* **9**:486–493.
14. Hookey, J. V., J. F. Richardson, and B. D. Cookson. 1998. Molecular typing of *Staphylococcus aureus* based on PCR-restriction fragment length polymorphism and DNA sequence analysis of the coagulase gene. *J. Clin. Microbiol.* **36**:1083–1089.
15. Ito, T., and K. Hiramatsu. 1998. Acquisition of methicillin resistance and progression of multiantibiotic resistance in methicillin-resistant *Staphylococcus aureus*. *Yonsei Med. J.* **39**:526–533.
16. Kreiswirth, B., J. Kornblum, R. D. Arbeit, W. Eisner, J. N. Maslow, A. McGeer, D. E. Low, and R. P. Novick. 1993. Evidence for a clonal origin of methicillin resistance in *Staphylococcus aureus*. *Science* **259**:227–230.
17. Musser, J. M., and V. Kapur. 1992. Clonal analysis of methicillin-resistant *Staphylococcus aureus* strains from intercontinental sources: association of the *mec* gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination. *J. Clin. Microbiol.* **30**:2058–2063.
18. Roberts, R. B., A. de Lencastre, W. Eisner, E. P. Severina, B. Shopsin, B. N. Kreiswirth, A. Tomasz, et al. 1998. Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in 12 New York hospitals. *J. Infect. Dis.* **178**:164–171.
19. Sa-Leao, R., I. Santos Sanches, D. Dias, I. Peres, R. M. Barros, and H. de Lencastre. 1999. Detection of an archaic clone of *Staphylococcus aureus* with low-level resistance to methicillin in a pediatric hospital in Portugal and in international samples: relics of a formerly widely disseminated strain? *J. Clin. Microbiol.* **37**:1913–1920.
20. Tesch, W., A. Strassle, B. Berger-Bachi, D. O'Hara, P. Reynolds, and F. H. Kayser. 1988. Cloning and expression of methicillin resistance from *Staphylococcus epidermidis* in *Staphylococcus carnosus*. *Antimicrob. Agents Chemother.* **32**:1494–1499.
21. Wielders, C. L., M. R. Vriens, S. Brisse, L. A. de Graaf-Miltenburg, A. Troelstra, A. Fleer, F. J. Schmitz, J. Verhoef, and A. C. Fluit. 2001. Evidence for in-vivo transfer of *mecA* DNA between strains of *Staphylococcus aureus*. *Lancet* **357**:1674–1675.
22. Witte, W., M. Enright, F. J. Schmitz, C. Cuny, C. Bräulke, and D. Heuck. 2001. Characteristics of a new epidemic MRSA in Germany ancestral to United Kingdom EMRSA 15. *Int. J. Med. Microbiol.* **290**:677–682.